[go: up one dir, main page]

ES2169030T3 - Envases de anticonceptivos que contienen estrogeno y progestina. - Google Patents

Envases de anticonceptivos que contienen estrogeno y progestina.

Info

Publication number
ES2169030T3
ES2169030T3 ES93107794T ES93107794T ES2169030T3 ES 2169030 T3 ES2169030 T3 ES 2169030T3 ES 93107794 T ES93107794 T ES 93107794T ES 93107794 T ES93107794 T ES 93107794T ES 2169030 T3 ES2169030 T3 ES 2169030T3
Authority
ES
Spain
Prior art keywords
strogen
progestine
packaging containers
containers containing
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93107794T
Other languages
English (en)
Inventor
Robert F Casper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jencap Research Ltd
Original Assignee
Jencap Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25671520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2169030(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 547744 external-priority patent/CA1332228C/en
Priority claimed from CA000547743A external-priority patent/CA1332227C/en
Application filed by Jencap Research Ltd filed Critical Jencap Research Ltd
Application granted granted Critical
Publication of ES2169030T3 publication Critical patent/ES2169030T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

ESTE INVENTO SE REFIERE A UNA FORMULACION CONTRACEPTIVA Y UN METODO DE CONTRACEPCION QUE EMPLEA UNA COMBINACION DE ESTROGENO Y PROGESTINA Y EN DONDE UN PERIODO CORTO DE ACTIVIDAD ESTROGENICA RELATIVAMENTE DOMINANTE SE ALTERNA CON UN PERIODO CORTO DE ACTIVIDAD PROGESTAGENICA RELATIVAMENTE DOMINANTE. EL INVENTO SE REFIERE TAMBIEN A FORMULACION DE SUSTITUCION HORMONAL PARA USO EN MUJERES MENOPAUSICAS O QUE HAN SUFRIDO ABLACION; DICHA FORMULACION EMPLEA UNA COMBINACION SIMILAR DE ESTROGENO Y PROGESTINA.
ES93107794T 1987-09-24 1988-09-23 Envases de anticonceptivos que contienen estrogeno y progestina. Expired - Lifetime ES2169030T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 547744 CA1332228C (en) 1987-09-24 1987-09-24 Formulation and method for estrogen replacement therapy
CA000547743A CA1332227C (en) 1987-09-24 1987-09-24 Oral contraceptive formulation

Publications (1)

Publication Number Publication Date
ES2169030T3 true ES2169030T3 (es) 2002-07-01

Family

ID=25671520

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93107794T Expired - Lifetime ES2169030T3 (es) 1987-09-24 1988-09-23 Envases de anticonceptivos que contienen estrogeno y progestina.
ES88308840T Expired - Lifetime ES2061672T3 (es) 1987-09-24 1988-09-23 Preparado hormonal y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES88308840T Expired - Lifetime ES2061672T3 (es) 1987-09-24 1988-09-23 Preparado hormonal y su uso.

Country Status (13)

Country Link
EP (2) EP0309263B1 (es)
JP (2) JP3314207B2 (es)
KR (1) KR0170764B1 (es)
CN (1) CN1042296C (es)
AT (1) ATE209919T1 (es)
AU (2) AU630334B2 (es)
DE (2) DE3856508T2 (es)
DK (1) DK174071B1 (es)
ES (2) ES2169030T3 (es)
FI (1) FI101601B1 (es)
HU (1) HU214598B (es)
NO (1) NO301689B1 (es)
NZ (1) NZ226316A (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738620A1 (de) * 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
AU8166191A (en) * 1990-08-10 1992-02-13 Ortho Pharmaceutical Corporation Method for treatment of bone wasting diseases
DE4104385C1 (es) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
EP0675720A1 (en) * 1992-12-28 1995-10-11 Jencap Research Limited Transdermal, multiphasic hormone replacement therapy
ES2227523T3 (es) * 1993-01-19 2005-04-01 Endorecherche Inc. Usos terapeuticos y sistemas de suministro de deshidroepiandrosterona.
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4405591C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
DE4405590C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
BR9710565A (pt) * 1996-07-26 1999-08-17 American Home Prod Contraceptivo oral
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
JP2001513566A (ja) * 1997-08-27 2001-09-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 経口避妊における、エストロゲンと子宮内膜節約性プロゲスチンおよび子宮内膜萎縮性プロゲスチンとの組み合わせ物
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE19831263A1 (de) * 1998-07-11 2000-01-13 Lohmann Therapie Syst Lts Darreichungsform
DE19911799A1 (de) * 1999-03-17 2000-09-28 Lohmann Therapie Syst Lts Sammelpackung zur Entnahme von befüllten Beuteln in vorgebener Reihenfolge
CA2267743C (en) 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
AU2005201151B2 (en) * 1999-03-30 2008-01-10 Jencap Research Ltd Low dose estrogen interrupted hormone replacement therapy
DE19934433A1 (de) 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
YU13902A (sh) * 1999-08-31 2006-01-16 Schering Ag. Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
CA2478194A1 (en) * 2002-03-11 2003-09-25 Janssen Pharmaceutica N.V. Continuous sulfatase inhibiting progestogen hormone replacement therapy
WO2004019954A1 (en) * 2002-08-28 2004-03-11 Robert Casper Estrogen replacement regimen
US7576226B2 (en) 2003-06-30 2009-08-18 Richter Gedeon Vegyeszeti Gyar Rt. Process of making isomers of norelgestromin and methods using the same
HUP0301981A2 (hu) * 2003-06-30 2005-04-28 Richter Gedeon Vegyészeti Gyár Rt. Tiszta d-(17alfa)-13-etil-17-hidroxi-18,19-dinor-pregn-4-én-20-in-3-on-3E- és 3Z-oxim izomerek, valamint eljárás az izomer keverékek és a tiszta izomerek előállítására
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
TW200603813A (en) * 2004-07-07 2006-02-01 Wyeth Corp Cyclic progestin regimens and kits
AU2012234682A1 (en) * 2011-03-25 2013-10-10 Universite Laval Inhibitors of 17beta-HSD1, 17beta-HSD3 and 17beta-HSD10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3568828A (en) * 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3836651A (en) * 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
DE2645307A1 (de) * 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
US4291028A (en) * 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4425339A (en) 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
FR2589735A1 (fr) * 1985-11-07 1987-05-15 Beillon Xavier Compositions anticonceptionnelles contenant un oestrogene et un progestatif
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet

Also Published As

Publication number Publication date
AU2276088A (en) 1989-04-06
FI101601B (fi) 1998-07-31
DK529688A (da) 1989-05-25
DE3888269D1 (de) 1994-04-14
NO301689B1 (no) 1997-12-01
FI884378L (fi) 1989-03-25
DK529688D0 (da) 1988-09-23
CN1041528A (zh) 1990-04-25
NZ226316A (en) 1991-10-25
JP3314207B2 (ja) 2002-08-12
DE3856508T2 (de) 2002-06-06
EP0309263A2 (en) 1989-03-29
CN1042296C (zh) 1999-03-03
JPH01132523A (ja) 1989-05-25
EP0309263A3 (en) 1989-08-02
NO884230D0 (no) 1988-09-23
JPH11286446A (ja) 1999-10-19
DE3888269T2 (de) 1994-07-07
EP0559240B1 (en) 2001-12-05
IE20030160A1 (en) 2003-07-09
FI101601B1 (fi) 1998-07-31
JP3208482B2 (ja) 2001-09-10
DE3856508D1 (de) 2002-01-17
EP0309263B1 (en) 1994-03-09
EP0559240A2 (en) 1993-09-08
EP0559240A3 (en) 1993-12-22
KR0170764B1 (ko) 1999-02-01
HUT50043A (en) 1989-12-28
DK174071B1 (da) 2002-05-21
FI884378A0 (fi) 1988-09-23
AU630334B2 (en) 1992-10-29
KR890004723A (ko) 1989-05-09
NO884230L (no) 1989-03-28
AU3044892A (en) 1993-02-11
HU214598B (hu) 1998-04-28
ATE209919T1 (de) 2001-12-15
ES2061672T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
ES2169030T3 (es) Envases de anticonceptivos que contienen estrogeno y progestina.
MX165436B (es) Composiciones para el cuidado de la piel
ES2032860T3 (es) Adsorbatos medicamentosos con surfactante y su preparacion.
PE113299A1 (es) Un metodo para mantener o mejorar la salud de la piel
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
ES2055175T3 (es) Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
HU900108D0 (en) Composition of controlled active ingredient delivery, operating by hydrogel
DK59182A (da) Farmaceutiske midler med kontinuerlig frigoerelse
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
EG18379A (en) Novel pharmacological compounds
AR240399A1 (es) Dispositivo suministrador para administrar una formulacion de agente beneficioso a un ambiente de uso.
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
PT100409A (pt) Utilizacao de inibidores de aromatase, por exemplo derivados de imidazopiridina, para a anticoncepcao em primatas femeas sem afectar o ciclo menstrual
ES2156122T3 (es) Agentes gelificantes de xantano.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2038289T3 (es) Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
BR8505469A (pt) Agente pressurizado de fornecimento para higiene oral
EP0318948A3 (en) Cleavable immunoconjugates for the delivery and release of agents in native form
NO891220D0 (no) Middel som inneholder salicylsyre for behandling av lepidose.
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
ES2014518A6 (es) Procedimiento para la produccion de una composicion farmaceutica de liberacion retardada.
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.
ES2059756T3 (es) Composiciones farmaceuticas que contienen primicina.
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 559240

Country of ref document: ES